Karla Palmer and Charlie Snow of Hyman, Phelps & McNamara published a two-part primer (Part 1 & Part 2) on the peptide compounding landscape this week, and it largely validates what we've been saying. The short version: there is real movement, but the path from here to regulated peptide compounding is longer and more complex than the current headlines suggest. The PCAC meeting in July is a necessary procedural step, not a finish line. Even if the committee recommends adding peptides to the 503A bulks list and FDA agrees, formal notice-and-comment rulemaking is still required – a process that could take more than a year. The supply chain problem we've flagged before remains unsolved. And advertising restrictions will apply regardless of what happens to the list.
Worth noting for those following closely: the PCAC currently has only three voting members and no chair against an authorized slate of up to 12 – a concern we've raised before, and one the firm flags as well. Also worth knowing: stakeholders have until July 9 to submit written comments to the docket, and until June 30 to notify FDA of intent to make oral presentations. If you have a perspective on any of the peptides under review, now is the time to make it heard.
The one wildcard, per the firm's analysis: Secretary Kennedy arguably has the statutory authority to place certain peptides in Category 1 unilaterally, bypassing the standard advisory committee process in the interest of public health. Whether he chooses to use it remains to be seen. Until then, the window for regulated compounded peptides is not yet fully open – and getting there will require more than political momentum.